Healthtech Late Stage Investors & VC Firms
847 firms in this list, with a median first check of $1M. 197 of them lead rounds. Generated from verified public data and updated continuously.
Apposite Capital
LondonGrowth–Late Stage
17 people
Gresham House Ventures
LondonSeed–Late Stage$1.3M – $26M
11 people
BIOSPRING PARTNERS
New YorkGrowth–Late Stage
22 people
Dimension Capital
San FranciscoSeed–Late Stage$1M – $10M
13 people
Quan Capital
ShanghaiSeed–Late Stage
16 people
Magnum Industrial Partners Tres S.L.
MadridGrowth–Late Stage
15 people
Ajax Health
Menlo ParkSeed–Late Stage
23 people
Goodwater Capital
BurlingamePre-Seed–Late Stage$5M – $50M
10 people
Good AI Capital
Seed–Late Stage
20 people
Heal Capital
BerlinPre-Seed–Late Stage$1M – $5M
13 people
Lauxera Capital Partners
ParisGrowth–Late Stage$22M – $110M
16 people
MaRS
TorontoPre-Seed–Late Stage
19 people
Mountain Group Capital
NashvillePre-Seed–Late Stage
13 people
Informed Ventures Advisors, Llc
Menlo ParkPre-Seed–Late Stage
8 people
LVX Ventures
BangalorePre-Seed–Late Stage
Allumia Ventures
SeattleSeries A–Late Stage$5M – $15M
11 people
MK Capital
NorthfieldSeed–Late Stage$2M – $10M
7 people
Yabeo
PullachSeed–Late Stage
13 people
Ascendo Ventures
SeoulPre-Seed–Late Stage
9 people
Delos Capital
CambridgeSeed–Late Stage
12 people
Mission Bay Capital
San FranciscoPre-Seed–Late Stage
14 people
Asahi Kasei Corporate Venture Capital
Menlo ParkPre-Seed–Late Stage$500K – $3M
19 people
Vensana Capital
MinneapolisSeries A–Late Stage
13 people
Hundreds Capital
BeijingSeed–Late Stage
3 people
Related lists
Healthtech Investors & VC Firms (3208)Late Stage Investors & VC Firms (2864)Healthtech Seed Investors & VC Firms (2488)Healthtech Series A Investors & VC Firms (2210)Healthtech Investors & VC Firms in United States (1616)Healthtech Pre-Seed Investors & VC Firms (1328)Healthtech Series B Investors & VC Firms (1216)Healthtech Growth Investors & VC Firms (1213)Late Stage Investors & VC Firms in United States (1101)Late Stage Investors & VC Firms in Global (857)
Data sourced from public filings and firms' own websites — see our methodology.











































































